1887

Graphical Abstract

Graphical abstract

(a). The classic ‘fried-egg’ colonies are commonly seen with the growth of on agar. (b). Scanning electron micrograph of demonstrates spindle-shaped cells with attachment organelles. is equipped with a repertoire of virulence factors, which include the production of the community-acquired respiratory distress syndrome toxin, formation of H0 and HS, the immunoglobulin-binding protein of , adhesion and antigenic variability via the P1 adhesin and associated surface proteins and the ability to form biofilms on surfaces.

Abstract

is a leading cause of community-acquired pneumonia among school-aged children and young adults. Infections occur throughout the year but tend to surge during winter months across Europe. A characteristic epidemic cycle, where a substantial surge in the number of infections occurs, is seen approximately every 1–4 years and hypothesized to be driven by changes in immunity and a shift in circulating variants. Once thought to be an organism of low virulence, it has now been found to possess several virulence factors, including toxin production, biofilm formation and evasion of antibody-mediated immunity. The lack of a cell wall and reduced metabolic pathways limit the options for antibiotic treatment. Acquired macrolide resistance is a growing concern, with >80% of cases in China being macrolide-resistant. Although efforts have been made to develop a vaccine, there are still substantial hurdles to overcome in relation to vaccine-enhanced disease, which results from an inappropriate immune response among vaccinated individuals.

Funding
This study was supported by the:
  • Swiss National Science Foundation (SNSF) (Award IICT)
    • Principle Award Recipient: PatrickM Meyer Sauteur
  • European Society of Clinical Microbiology and Infectious Diseases (Award ESCMID SG Collaboration Grant 2024)
    • Principle Award Recipient: PatrickM Meyer Sauteur
  • European Society of Clinical Microbiology and Infectious Diseases (Award ESCMID SG Collaboration Grant 2024)
    • Principle Award Recipient: MichaelL Beeton
  • European Society of Clinical Microbiology and Infectious Diseases (Award ESCMID Study Group Grant)
    • Principle Award Recipient: MichaelL Beeton
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. The Microbiology Society waived the open access fees for this article.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001910
2024-10-30
2024-11-03
Loading full text...

Full text loading...

/deliver/fulltext/jmm/73/10/jmm001910.html?itemId=/content/journal/jmm/10.1099/jmm.0.001910&mimeType=html&fmt=ahah

References

  1. Eaton MD, Meiklejohn G, van Herick W. Studies on the etiology of primary atypical pneumonia: a filterable agent transmissible to cotton rats, hamsters, and chick embryos. J Exp Med 1944; 79:649–668 [View Article] [PubMed]
    [Google Scholar]
  2. Saraya T. The history of Mycoplasma pneumoniae pneumonia. Front Microbiol 2016; 7:178909 [View Article]
    [Google Scholar]
  3. Chanock RM, Dienes L, Eaton MD, Edward D ff., Freundt EA et al. Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organism (Eaton Agent). Science 1963; 140:662 [View Article]
    [Google Scholar]
  4. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17:697–728 [View Article] [PubMed]
    [Google Scholar]
  5. Ueda N, Minami S, Akimoto M. Mycoplasma pneumoniae-associated mild encephalitis/encephalopathy with a reversible splenial lesion: report of two pediatric cases and a comprehensive literature review. BMC Infect Dis 2016; 16:671 [View Article] [PubMed]
    [Google Scholar]
  6. Meyer Sauteur PM, Unger WW, Nadal D, Berger C, Vink C et al. Infection with and carriage of Mycoplasma pneumoniae in children. Front Microbiol 2016; 7:186040 [View Article]
    [Google Scholar]
  7. Gaspari E, Malachowski A, Garcia-Morales L, Burgos R, Serrano L et al. Model-driven design allows growth of Mycoplasma pneumoniae on serum-free media. NPJ Syst Biol Appl 2020; 6:33 [View Article] [PubMed]
    [Google Scholar]
  8. Xiao L, Ptacek T, Osborne JD, Crabb DM, Simmons WL et al. Comparative genome analysis of Mycoplasma pneumoniae. BMC Genom 2015; 16:610 [View Article] [PubMed]
    [Google Scholar]
  9. Dumke R. Molecular tools for typing Mycoplasma pneumoniae and Mycoplasma genitalium. Front Microbiol 2022; 13: [View Article]
    [Google Scholar]
  10. Kenri T, Yamazaki T, Ohya H, Jinnai M, Oda Y et al. Genotyping of Mycoplasma pneumoniae strains isolated in Japan during 2019 and 2020: spread of p1 gene type 2c and 2j variant strains. Front Microbiol 2023; 14:1202357 [View Article]
    [Google Scholar]
  11. Dumke R, Catrein I, Herrmann R, Jacobs E. Preference, adaptation and survival of Mycoplasma pneumoniae subtypes in an animal model. Int J Med Microbiol 2004; 294:149–155 [View Article] [PubMed]
    [Google Scholar]
  12. Meyer Sauteur PM. Childhood community-acquired pneumonia. Eur J Pediatr 2023; 1:1–8 [View Article]
    [Google Scholar]
  13. Spuesens EBM, Fraaij PLA, Visser EG, Hoogenboezem T, Hop WCJ et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 2013; 10:e1001444 [View Article] [PubMed]
    [Google Scholar]
  14. Dumke R, Benitez AJ, Chalker V, Gullsby K, Henrich B et al. Multi-center evaluation of one commercial and 12 in-house real-time PCR assays for detection of Mycoplasma pneumoniae. Diagn Microbiol Infect Dis 2017; 88:111–114 [View Article] [PubMed]
    [Google Scholar]
  15. Overview | Pneumonia (community-acquired): antimicrobial prescribing | Guidance | NICE. n.d https://www.nice.org.uk/guidance/ng138 accessed 29 January 2024
  16. Todd SR, Dahlgren FS, Traeger MS, Beltrán-Aguilar ED, Marianos DW et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr 2015; 166:1246–1251 [View Article] [PubMed]
    [Google Scholar]
  17. Pánisová E, Unger WW, Berger C, Meyer Sauteur PM. Mycoplasma pneumoniae-specific IFN-γ-producing CD4+ effector-memory T cells correlate with pulmonary disease. Am J Respir Cell Mol Biol 2021; 64:143–146 [View Article]
    [Google Scholar]
  18. Meyer Sauteur PM, Trück J, van Rossum AMC, Berger C. Circulating antibody-secreting cell response during Mycoplasma pneumoniae childhood pneumonia. J Infect Dis 2020; 222:136–147 [View Article] [PubMed]
    [Google Scholar]
  19. Meyer Sauteur PM, Krautter S, Ambroggio L, Seiler M, Paioni P et al. Improved diagnostics help to identify clinical features and biomarkers that predict Mycoplasma pneumoniae community-acquired pneumonia in children. Clin Infect Dis 2020; 71:1645–1654 [View Article]
    [Google Scholar]
  20. Ding G, Zhang X, Vinturache A, van Rossum A, Yin Y et al. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Eur J Pediatr 2024; 183:3001–3011 [View Article]
    [Google Scholar]
  21. Pereyre S, Tardy F. Integrating the human and animal sides of Mycoplasmas resistance to antimicrobials. Antibiotics 2021; 10:1216 [View Article] [PubMed]
    [Google Scholar]
  22. Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 2016; 7:974 [View Article] [PubMed]
    [Google Scholar]
  23. CLSI Methods for antimicrobial susceptibility testing for human Mycoplasmas. Approved guideline. CLSI document M43-A; 2011
  24. Dégrange S, Renaudin H, Charron A, Pereyre S, Bébéar C et al. Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J Antimicrob Chemother 2008; 61:1390–1392 [View Article] [PubMed]
    [Google Scholar]
  25. Gruson D, Pereyre S, Renaudin H, Charron A, Bébéar C et al. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother 2005; 49:1190 [View Article]
    [Google Scholar]
  26. Feng M, Schaff AC, Balish MF. Mycoplasma pneumoniae biofilms grown in vitro: traits associated with persistence and cytotoxicity. Microbiology 2020; 166:629–640 [View Article]
    [Google Scholar]
  27. Somarajan SR, Al-Asadi F, Ramasamy K, Pandranki L, Baseman JB et al. Annexin A2 mediates Mycoplasma pneumoniae community-acquired respiratory distress syndrome toxin binding to eukaryotic cells. mBio 2014; 5: [View Article]
    [Google Scholar]
  28. Kannan TR, Musatovova O, Balasubramanian S, Cagle M, Jordan JL et al. Mycoplasma pneumoniae community acquired respiratory distress syndrome toxin expression reveals growth phase and infection-dependent regulation. Mol Microbiol 2010; 76:1127–1141 [View Article] [PubMed]
    [Google Scholar]
  29. Simmons WL, Daubenspeck JM, Osborne JD, Balish MF, Waites KB et al. Type 1 and type 2 strains of Mycoplasma pneumoniae form different biofilms. Microbiology 2013; 159:737–747 [View Article]
    [Google Scholar]
  30. Blötz C, Singh N, Dumke R, Stülke J. Characterization of an Immunoglobulin Binding Protein (IbpM) From Mycoplasma pneumoniae. Front Microbiol 2020; 11:685 [View Article] [PubMed]
    [Google Scholar]
  31. Grover RK, Zhu X, Nieusma T, Jones T, Boreo I et al. A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union. Science 2014; 343:656–661 [View Article] [PubMed]
    [Google Scholar]
  32. Lluch-Senar M, Cozzuto L, Cano J, Delgado J, Llórens-Rico V et al. Comparative “-omics” in Mycoplasma pneumoniae clinical isolates reveals key virulence factors. PLoS One 2015; 10:e0137354 [View Article] [PubMed]
    [Google Scholar]
  33. Nguipdop-Djomo P, Fine PEM, Halsby KD, Chalker VJ, Vynnycky E. Cyclic epidemics of Mycoplasma pneumoniae infections in England and Wales from 1975 to 2009: time-series analysis and mathematical modelling. Lancet 2013; 382:S78 [View Article]
    [Google Scholar]
  34. Edelstein I, Rachina S, Touati A, Kozlov R, Henin N et al. Mycoplasma pneumoniae monoclonal P1 type 2c outbreak, Russia, 2013. Emerg Infect Dis 2016; 22:348–350 [View Article] [PubMed]
    [Google Scholar]
  35. Pereyre S, Renaudin H, Charron A, Bébéar C. Clonal spread of Mycoplasma pneumoniae in Primary School, Bordeaux, France. Emerg Infect Dis 2012; 18:343–345 [View Article]
    [Google Scholar]
  36. Waller JL, Diaz MH, Petrone BL, Benitez AJ, Wolff BJ et al. Detection and characterization of Mycoplasma pneumoniae during an outbreak of respiratory illness at a university. J Clin Microbiol 2014; 52:849–853 [View Article] [PubMed]
    [Google Scholar]
  37. Beeton ML, Zhang X-S, Uldum SA, Bébéar C, Dumke R et al. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Euro Surveill 2020; 25:1900112 [View Article] [PubMed]
    [Google Scholar]
  38. Parrott GL, Kinjo T, Fujita J. A compendium for mycoplasma pneumoniae. Front Microbiol 2016; 7:179935 [View Article]
    [Google Scholar]
  39. Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M et al. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill 2022; 27:19 [View Article]
    [Google Scholar]
  40. Meyer Sauteur PM, Beeton ML. ESGMAC the ESGMAC MAPS study group Mycoplasma pneumoniae: gone forever?. Lancet Microbe 2023; 4:e763 [View Article] [PubMed]
    [Google Scholar]
  41. Sauteur PMM, Chalker VJ, Berger C, Nir-Paz R, Beeton ML et al. Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?. Lancet Microbe 2022; 3:e897 [View Article]
    [Google Scholar]
  42. Bolluyt DC, Euser SM, Souverein D, van Rossum AM, Kalpoe J et al. Increased incidence of Mycoplasma pneumoniae infections and hospital admissions in the Netherlands, November to December 2023. Euro Surveill 2024; 29:2300724 [View Article] [PubMed]
    [Google Scholar]
  43. Li H, Li S, Yang H, Chen Z, Zhou Z. Resurgence of Mycoplasma pneumonia by macrolide-resistant epidemic clones in China. Lancet Microbe 2024; 5:e515 [View Article] [PubMed]
    [Google Scholar]
  44. Meyer Sauteur PM, Beeton ML. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. Lancet Microbe 2024; 5:e100–e101 [View Article] [PubMed]
    [Google Scholar]
  45. Nordholm AC, Søborg B, Jokelainen P, Lauenborg Møller K, Flink Sørensen L et al. Mycoplasma pneumoniae epidemic in Denmark, October to December, 2023. Euro Surveill 2024; 29:2300707 [View Article] [PubMed]
    [Google Scholar]
  46. Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. Nat Rev Microbiol 2012; 10:459–471 [View Article] [PubMed]
    [Google Scholar]
  47. Bébéar C, Raherison C, Nacka F, de Barbeyrac B, Pereyre S et al. Comparison of Mycoplasma pneumoniae infections in asthmatic children versus asthmatic adults. Pediatr Infect Dis J 2014; 33:e71–5 [View Article] [PubMed]
    [Google Scholar]
  48. Smith CB, Chanock RM, Friedewald WT, Alford RH. Mycoplasma pneumoniae infections in volunteers. Ann N Y Acad Sci 1967; 143:471–483 [View Article] [PubMed]
    [Google Scholar]
  49. Gavitt TD, Mara AB, Goodridge ML, Ozyck RG, Reinhardt E et al. B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs. NPJ Vaccines 2022; 7:130 [View Article] [PubMed]
    [Google Scholar]
  50. Mara AB, Gavitt TD, Tulman ER, Geary SJ, Szczepanek SM. Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease. NPJ Vaccines 2020; 5:31 [View Article] [PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001910
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error